1234015-62-3 Usage
Chemical structure
A complex organic compound derived from 1,3-bis(methylsulfonyl)-2-propen-1-one, containing methoxy and phenyl groups.
Methoxy groups (-OCH3)
Two methoxy groups are present in the molecule.
Phenyl groups (C6H5)
One phenyl group is attached to the methoxy group.
Methylsulfonyl groups (-S(O)2CH3)
Two methylsulfonyl groups are present in the molecule.
Carbonyl group (C=O)
The carbonyl group is part of the 2-propen-1-one structure.
Appearance
Likely a solid or oily substance, but specific appearance is not provided.
Solubility
Not specified, but may be soluble in organic solvents due to its nonpolar nature.
Stability
Likely stable under normal conditions, but further research is needed to confirm.
Reactivity
May react with nucleophiles, electrophiles, or other reactive species, but specific reactivity is not provided.
Applications
Potentially used in scientific research and pharmaceutical development due to its unique structure and potential medicinal properties.
Further research
More in-depth research and analysis are needed to determine specific uses and properties of the compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1234015-62-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,4,0,1 and 5 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1234015-62:
(9*1)+(8*2)+(7*3)+(6*4)+(5*0)+(4*1)+(3*5)+(2*6)+(1*2)=103
103 % 10 = 3
So 1234015-62-3 is a valid CAS Registry Number.
1234015-62-3Relevant articles and documents
3, 5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINASE INHIBITORS AND USES THEREOF
-
Page/Page column 22; 32, (2021/03/13)
The disclosure provides novel compounds as represented in Formula (I), wherein A0-A2, R0-R6, L, Z and Q are defined herein. The compounds of Formula (I) are CHK1 inhibitors. Therefore, the compounds of the discl
COMPOUNDS USEFUL FOR INHIBITING CHK1
-
Page/Page column 12, (2011/06/26)
The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof or a solvate of the salt, that inhibits Chk1 and is useful in the treatment of cancer.
